PAN-90806 ( CP-547632;CP547632 )

产品货号. M13744 CAS No. 252003-65-9

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

拼团产品询价大包装询价加入购物车

产品名称

PAN-90806
注意事项

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
产品简述

PAN-90806 (CP-547632, CP547632) is a highly potent, ATP-competitive, orally active VEGFR-2 inhibitor that blocks VEGFR-2 kinase autophosphorylation (IC50=11 nM) and VEGF-induced VEGFR-2 phosphorylation (IC50=5 nM).
产品描述

PAN-90806 (CP-547632, CP547632) is a highly potent, ATP-competitive, orally active VEGFR-2 inhibitor that blocks VEGFR-2 kinase autophosphorylation (IC50=11 nM) and VEGF-induced VEGFR-2 phosphorylation (IC50=5 nM); is approximately equipotent (<10-fold) against VEGFR-2, bFGF receptor and EGFR/Tie-2 chimera, 250-1000-fold selectivity over PDGFRβ, EGFR and InsR; inhibits tumor-associated VEGFR-2 phosphorylation with decreased microvascular density and significant tumor growth inhibition in a number of tumor models.
同义词

CP-547632;CP547632
通路

Angiogenesis
靶点

VEGFR
受体

VEGFR
研究领域

Other Indications
适应症

Other Disease

CAS Number

252003-65-9
分子量

532.40
分子式

C20H24BrF2N5O3S
纯度

>98% (HPLC)
溶解度

——
SMILES

O=C(C1=C(NC(NCCCCN2CCCC2)=O)SN=C1OCC3=C(F)C=C(Br)C=C3F)N
化学全称

3-((4-bromo-2,6-difluorobenzyl)oxy)-5-(3-(4-(pyrrolidin-1-yl)butyl)ureido)isothiazole-4-carboxamide

1. Beebe JS, et al. Cancer Res. 2003 Nov 1;63(21):7301-9.
2. Cohen RB, et al. Cancer Chemother Pharmacol. 2007 Jun;60(1):81-9.

计算器

产品手册

关联产品

8-O-Acetylshanzhisid...

8-O-Acetylshanzhiside methylester has potential against cerebral ischemic injury, and its protective effect on oxygen-glucose deprivation-induced injury might be due to the suppression of intracellular Ca2+ elevation and caspase-3 activity.
PAN-90806

PAN-90806 (CP-547632, CP547632) is a highly potent, ATP-competitive, orally active VEGFR-2 inhibitor that blocks VEGFR-2 kinase autophosphorylation (IC50=11 nM) and VEGF-induced VEGFR-2 phosphorylation (IC50=5 nM).
Pazopanib

A potent, orally available, pan-VEGFR inhibitor with IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively.